Unresectable Hepatocellular Carcinoma
Conditions
Interventions
SBRT:Stereotactic Body Radiation Therapy (SBRT)
SBRT combined with Tetrandrine:Stereotactic Body Radiation Therapy (SBRT) combined with Tetrandrine
Sponsors
Zhongshan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. age 18-75 years; 2. ECOG performance status (PS) 0-2; 3. expecting survival time longer than 3 months; 4. Patients with pathologically confirmed hepatocellular carcinoma; or had clinical features of patients with a clinical diagnosis of hepatocellular carcinoma; 5. CT, MRI and (or) B-ultrasound comfirmed unresectable hepatocellular carcinoma confined to the liver with or without portal vein tumor thrombus; 6. no history of abdominal radiotherapy; 7. adequate bone marrow-absolute neutrophil count (ANC); 1500 cells/mm3, platelet count: 100,000 cells/mm3, and hemoglobin: 10 g/dL; 8. kidney function (serum creatinine less than 115 umol/L), liver function (serum total bilirubin less than 34 umol/L) and Child-Pugh A or B; 9. Patients with intrahepatic multiple HCC and lipiodol deposition was not well after interventional therapy.
Exclusion criteria
Exclusion criteria: 1. Patients will be ruled out if inconsistent with any one of enter criterion; 2. with distant metastatic disease; 3. Patients with prior malignancy were ineligible for the study, with the exception of those who had experienced nonmelanoma skin cancer, in situ cancer of the cervix, or other cancer for which the patient had been disease free for longer than 5 yr; 4. Obstructive jaundice without external biliary drainage or patients with uncontrolled infection or diabetes mellitus; 5. had received abdominal irradiation before; 6. Poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tetrandrine Tablets; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival time;AFP reaction; | — |
Contacts
Public ContactZeng Zhaochong
Outcome results
None listed